Paul A. Friedman - 21 Jul 2021 Form 4 Insider Report for ALEXION PHARMACEUTICALS, INC.

Reporting relationship: Director
Issuer ticker: N/A
Reported as of: 21 Jul 2021
Net transaction value: $0
SEC form: 4
Accepted by SEC: 23 Jul 2021, 16:51:08 UTC
Prior SEC filing: 22 Jun 2021
Next SEC filing: 24 Feb 2022
Source filing: View source filing
Reporting owner signature: /s/ Douglas Barry, Attorney-in-Fact for Paul A. Friedman

Key filing fact

Paul A. Friedman filed Form 4 for ALEXION PHARMACEUTICALS, INC. on 23 Jul 2021.

Key facts

This page summarizes Paul A. Friedman's Form 4 filing for ALEXION PHARMACEUTICALS, INC..
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 23 Jul 2021, 16:51.

Change

Previous filing in this sequence was filed on 22 Jun 2021.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ALXN transaction

Common Stock, par value $.0001 per share

Disposed to Issuer

Transaction value: $0
Shares: -12,840
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 21 Jul 2021
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

Paul A. Friedman is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 1 footnote

Footnote F1

Represents shares of Alexion common stock disposed in connection with the Agreement and Plan of Merger (the "Merger Agreement") dated as of December 12, 2020, by and among Alexion and AstraZeneca PLC. In accordance with the Merger Agreement, upon the First Effective Time (as defined in the Merger Agreement), each share of Alexion common stock was converted into the right to receive (i) 2.1423 American Depositary Shares (ADSs) of AstraZeneca PLC and (ii) $60.00 in cash (the "Merger Consideration"). Upon the First Effective Time, 2,495 restricted stock units were fully vested and cancelled and converted into the right to receive the Merger Consideration with respect to each share of Alexion common stock subject to such restricted stock units.